1Dunford JE,Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing BPs. J Pharmacol Exp Ther ,2001,296 (2) :235-242.
2Fleisch H. Pharmacodynamics of bisphosphonates. In: Fleisch H. Bisphosphonates in bone disease. Third edition. San Diego: Academic Press,2000.30- 60.
3Chesnut Ⅲ CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004,19 (8): 1241-1249.
4Bauss F, Lalla S, Endele R, et al. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheuamatol, 2002,29(10) :2200-2208.
5Ringe JD, Dorst A, Faber H, et al. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford). 2003,42(6) :743-749.
6Koh LK. The diagnosis and management of hypercalcaemia. Ann Acad Med Singapore, 2003 ,32(1) :129-139.
7Fleisch H. Effects of bisphosphonates on bone resoption. In: Fleisch H. Bisphosphonates in bone diseases. Third edition . San Digego :Academic Press,2000. 34-38.
8Dumon JC, Journe F, Kheddoumi N, et al. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol, 2004 ,45(4) :521-528.
9Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des, 2003,9 (32) :2643-2658.
10Heikkil P, Teronen O, Moilanen M, et al. Bisphosphonates inhibit stromelysin-1 ( MMP-3 ), matrixmet alloelastase ( MMP-12 ), collagenase-3(MMP-13) and enamelysin (MMP-20) , but not urokinasetype plasminogen activator, and diminish invation and migration ofhuman malignant and endothelial cell lines. Anticancer Drugs,2002,13 (13) 245-254.
